Qiming Venture Partners has closed Qiming Venture Partners Fund VII, a new USD1.1 billion fund focused on early stage Healthcare and TMT investments.Qiming has again secured support from its long-term LP base in Fund VII as well as attracting several new LPs. As in prior funds, the vast majority of Qiming’s capital comes from a prestigious group of endowments, foundations, family offices, and private pensions.
Fund VII is led by Managing Partners Duane Kuang, Nisa Leung, William Hu, and Gary Rieschel, with investment and administrative teams based in Shanghai, Beijing, Shenzhen, and Hong Kong. Qiming anticipates investing Fund VII in domain areas such as biopharma, medtech, diagnostics, health care services, information technology, artificial intelligence, enterprise services, consumer internet and e-commerce.
Jim Millar, Managing Director at Princeton University Investment Company (PRINCO), says: “Qiming has developed a strong reputation and track record as a leading venture capital firm and is notable for its culture of partnership within the firm, with entrepreneurs, and with LPs.”
“Princeton is proud to have partnered with Qiming as an anchor investor since inception almost 15 years ago,” says Amy Zhou, Principal at PRINCO.
We are grateful to our existing and new LPs for the confidence they place in us by reaffirming their commitment to the Qiming platform and the opportunities we see in China. It is with the utmost respect and gratitude that the entire Qiming family thank them for their ongoing advice, support, and commitment.
“As the world combats the COVID-19 pandemic, we are proud that many of our portfolio companies play a critical role in providing products and services both to the front-line medical care as well as to the backend supports. Qiming is committed to continue investing in great entrepreneurs for the betterment of humanity. We take great pride in bringing long-term value to all societies.”
